Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules

International Journal of Oncology

Volumn 29, Issue 1, 2006, Pages 49-55

  Burke, Patricia A ^a   Gregg, Jeffrey P ^a   Bakhtiar, Brandon ^a   Beckett, Laurel A ^a   Denardo, Gerald L ^a   Albrecht, Huguette ^a   De Vere White, Ralph W ^a   De Nardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gleason grade; Glycosylation; Immunohistochemistry; MUC1; Prostate cancer; Tumor markers

Indexed keywords

MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; EPITOPE MAPPING; FEMALE; GLYCOSYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; PROSTATE TUMOR; PROTEIN PROCESSING; TISSUE MICROARRAY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPE MAPPING; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUCINS; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548262496     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.1.49     Document Type: Article

References (61)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Hanisch F-G and Muller S: MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449, 2000.
3. Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6: 339-353, 2002.
4. Zotter S, Hageman C, Lossnitzer A, Mooi WJ and Hilgers J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12: 55-101, 1988.
5. Brayman M, Thathiah A and Carson DD: MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2: 4-12, 2004.
6. McGuckin MA, Walsh MD, Hohn BG, Ward BG and Wright RG: Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26: 432-439, 1995.
7. Kraus S, Abel PD, Nachtmann C, Linsenmann H-J, Weidner W, Stamp GWH, Franke FE and Lalani E-N: MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 33: 60-67, 2002.
8. Reis CA, David L, Seixas M, Burchell J and Sobrinho-Simoes M: Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 79: 402-410, 1998.
9. Sakamoto H, Yonezawa S, Utsunomiya T, Tanaka S, Kim YS and Sato E: Mucin antigen expression in gastric carcinomas of young and old adults. Hum Pathol 28: 1056-1065, 1997.
10. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS and Sato E: Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4: 2605-2614, 1998.
11. Nakamori S, Ota DM, Cleary KR, Shirotani K and Irimura T: MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106: 353-361, 1994.
12. Leroy X, Zerimech F, Zini L, Copin M-C, Buisine M-P, Gosselin B, Aubert J-P and Porchet N: MUC1 expression is correlated with nuclear grade and tumor progession in a pT1 renal clear cell carcinoma. Am J Clin Pathol 118: 47-51, 2002.
13. Yonezawa S and Sato E: Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 47: 813-830, 1997.
14. Rassidakis GZ, Goy A, Medeiros LJ, Jiang Y, Thomaides A, Remache Y, Cabanillas F, Sarris AH and Gilles F: Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res 9: 2213-2220, 2003.
15. Taylor-Papadimitriou J, Burchell J, Miles DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta 1455: 301-313, 1999.
16. Bieche I and Lidereau R: A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogen 98: 75-80, 1997.
17. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C and Taylor-Papadimitriou J: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43: 1072-1076, 1989.
18. Mommers ECM, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J, Meijer CJL, Baak JPA and van Diest PJ: Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int J Cancer 84: 466-469, 1999.
19. Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H and Ceriani RL: Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 9: 221-235, 1990.
20. Burchell JM, Mungul A and Taylor-Papadimitriou J: O-linked glycosylation in the mammary gland: changes that occur during malignancy. J Mammary Gland Biol Neoplasia 6: 355-364, 2001.
21. Loyd KO, Burchell J, Kudryashov V, Yin BWT and Taylor- Papadimitriou J: Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J Biol Chem 271: 33325-33334, 1996.
22. Ceriani RL, Chan CM, Baratta FS, Ozzello L, De Rosa CM and Habif DV: Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer 51: 343-354, 1992.
23. Chan CM, Baratta FS, Ozzello L and Ceriani RL: Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 30: 243-261, 1994. (Pubitemid 24262119)
24. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, Miles D and Taylor-Papadimitriou J: An α2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 9: 1307-1311, 1999.
25. Brockhausen I, Yang J-M, Burchell J, Whitehouse C and Taylor-Papadimitriou J: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233: 607-617, 1995.
26. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R and Lamport D: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47: 5476-5482, 1987.
27. Ceriani RL, Peterson JA, Blank EW and Derek TA: Epitope expression on the breast epithelial mucin. Breast Cancer Res Treat 24: 103-113, 1992.
28. Ten Berge RL, Snijdewint FGM, von Mensdorff-Pouilly S, Poort-Keesom RJJ, Oudejans JJ, Meijer JWR, Willemze R, Hilgers J and Meijer CJL: MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 54: 933-939, 2001.
29. Cao Y, Blohm D, Ghadimi M, Stosiek P, Xing PX and Karsten U: Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelial reveal different and heterogeneous tumorassociated aberrations in glycosylation. J Histochem Cytochem 45: 1547-1557, 1997.
30. Kirschenbaum A, Itzkowitz SH, Wang JP, Eliashvili M and Levine AC: MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 3: 163-168, 1999.
31. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI and Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4: 295-302, 2001.
32. Burchell J and Taylor-Papadimitriou J: Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2: 155-162, 1993.
33. Tsuzuki T, Ujihira N and Ando T: Usefulness of epithelial membrane antigen (EMA) to discriminate between perineural invasion and perineural indentation in prostatic carcinoma. Histopathology 47: 159-165, 2005.
34. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, De Marzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD and Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2005.
35. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch M, Gasser TC and Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113: 619-628, 2005.
36. Arai T, Fujita K, Fujime M and Irimura T: Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol 12: 654-661, 2005.
37. O'Connor JC, Julian J, Lim SD and Carson DD: MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostat Dis 8: 36-44, 2005.
38. Papadopoulos I, Sivridis E, Giatromanolaki A and Koukourakis MI: Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 7: 1533-1538, 2001.
39. Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G and Lalani E-N: Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 4: 9-18, 2002.
40. Porowska H, Paszkiewicz-Gadek A, Woeczynski S and Gindzienski A: MUC1 expression in human breast cancer cells is altered by factors affecting cell proliferation. Neoplasma 49: 104-109, 2002.
41. Gleason DF and The Veteran's Administration Cooperative Urologic Research Group: Histological grading and clinical staging of prostatic carcinoma. In: The Prostate. Tannenbaum M (ed). Lea & Febiger, Philadelphia, pp171-197, 1977.
42. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imaj S, Haga S, Kiyozuka Y, Schol D, Meulenkroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB and Hilgers J: Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 19: 1-20, 1998.
43. Howell LP, De Nardo SJ, Levy N, Lund J and De Nardo GL: Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 10: 126-135, 1995.
44. Peterson JA, Larocca D, Walkup G, Amiya R and Ceriani RL: Molecular analysis of epitopic heterogeneity of the breast mucin. In: Breast Epithelial Antigens. Ceriani RL (ed). Plenum Publ. Corp., New York, pp55-68, 1991.
45. Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA and Ceriani RL: Initial clinical evaluation of radiolabeled MXDTPA humanized BrE-3 antibody in patients with advanced breast cancer. Clin Cancer Res 4: 1679-1688, 1998.
46. Blockzjil A, Nilsson K and Nilsson O: Epitope characterization of MUC1 antibodies. Tumor Biol 19: 46-56, 1998.
47. Karanikas V, Patton K, Jamieson G, Pietersz G and McKenzie I: Affinity of antibodies to MUC1 antigens. Tumor Biol 19: 71-78, 1998.
48. Hanisch F-G: Specificity clusters of MUC1-reactive mouse monoclonal antibodies. Tumor Biol 19: 111-117, 1998.
49. Sikut R, Sikut A, Zhang K, Baeckstrom D and Hansson GC: Reactivity of antibodies with highly glycosylated MUC1 mucins from colon carcinoma cells and biles. Tumour Biol 19: 122-126, 1998.
50. Reddish MA, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A and Longenecker BM: Analysis of the role of type 1 core O-Glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies. Tumor Biol 19: 57-66, 1998.
51. Cao Y, Karsten U and Hilgers J: Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon and breast tissues. Tumor Biol 19: 88-99, 1998.
52. Tytgat MA, Swallow DM, Jan-Willem B, Klinken V, Buller HA, Einerhand AW and Dekker J: Unpredictable behavior of mucins in SDS/polyacrylamide-gel electrophoresis. Biochem J 310: 1053-1054, 1995.
53. De Nardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL and De Nardo GL: Radioimmunotherapy for breast cancer using indium- 111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 38: 1180-1185, 1997.
54. Richman CM and De Nardo SJ: Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 38: 26-35, 2001.
55. 99mTc SM3 radioimmunoscintigraphy. Acta Oncol 35: 319-321, 1996.
56. Britton KE, Jan H, al-Yasi AR, Biassoni L, Carroll MJ and Granowska M: Efficacy of immunoscintigraphy for detection of lymph node metastases. Recent Results Cancer Res 157: 3-11, 2000.
57. Rahn JJ, Dabbagh L, Pasdar M and Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma. Cancer 91: 1973-1982, 2001.
58. Best CJM, Gillespie JW, Yi Y, Chandramouli GVR, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, Gonzalez S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR and Chuaqui RF: Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11: 6823-6834, 2005.
59. Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM and Campbell P: Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions. Biochemistry 41: 9946-9961, 2002.
60. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J and Ceriani RL: Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17-21, 1981.
61. Dai J, Allard WJ, Davis G and Yeung KK: Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin. Tumor Biol 19: 100-110, 1998.